Roche, Herzog&De MeuronM&ARoche makes takeover bid for Poseida Thera...Genentech, the US arm of Swiss-based Roche AG, plans to acquire its long-time partner in allogeneic CAR-T blood cancer and gene therapies, Poseida Therapeutics Inc, for up to US$1.5bn. more ➔
PharmaMar SAMarket AuthorisationEC ordered to pay cost of PharmaMar vs EMA...The General Court of the EU orders the European Commission to pay the costs in the case of Aplidin® against the Spanish company PharmaMar SA, in which an EU marketing authorisation was not granted due … more ➔
NOD-Proteindesign.Andreas Heddergott/TUM.jpgProtein EngineeringNew method set to speed up protein designResearcher from China, Germany and the US have developed a method for designing large new proteins with pre-defined properties in the lab using Alphafold2. more ➔
CertestDrug deliveryCircio Holding ASA inks collaboration agre...Circio Holding ASA has inked a collaboration with Certest Biotec, SL to find and test circVec LNP-formulations to deliver its circular RNA therapeutics to target tissues for gene therapies. more ➔
ConsiliumNovel FoodCountry alliance calls for EU protein str...A dispute is brewing in Europe over climate-friendly protein production in fermenters between EU member states that are in favour of or against protein production independent of agricultural land. Germany, … more ➔
FinanancingATB Therapeutics raises €54m in Series A...Belgian ADC specialist ATB Therapeutics BV has kicked off with €54m from EQT Life Sciences and MRL Ventures Fun to push its payload technology towards clinical development. more ➔
Innate Pharma SAAntibody engineeringTetraspecific B/NK cell better than T cell...Innate Pharma SA has presented promising preclinical data of its tetraspecific antibody-based B and NK cell engager IPH6501, a novel approach to treat B cell non-Hodgkin lymphoma (B-NHL). more ➔
AdaptimmuneClinical trialsAdaptimmune nears second approval for TCR-...After meeting the primary endpoints of a pivotal Phase II trial, UK-based Adaptimmune Ltd. is submitting an FDA Biologics License Application for its autologous T-cell receptor therapy (TCR-T) Lete-cel … more ➔
Qiagen NVHorizion EuropePharmahungary Group participates in ambiti...Pharmahungary Group has announced it will be participating in a project aiming to set up standardised methods to examine intercellular and interorgan communication via extracellular vesicles, the next … more ➔
Alentis TherapeuticsFinancingAlentis Therapeutics raises US$181.4m in S...Swiss Alentis Therapeutics has raised US$181.4m in an oversubscribed Series D financing set to boost clinical development of its anti-Claudin-1 ADCs in solid tumours. more ➔
Roche, Herzog&De Meuron
PharmaMar SA
NOD-Proteindesign.Andreas Heddergott/TUM.jpg
Certest
Consilium
Innate Pharma SA
Adaptimmune
Qiagen NV
Alentis Therapeutics